Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production

The mammalian target of rapamycin (mTOR) inhibiting drug rapamycin (Sirolimus) has severe side effects in patients including hyperlipidemia, an established risk factor for atherosclerosis. Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contribut...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Biochim Biophys Acta Mol Cell Biol Lipids
Egile Nagusiak: Fruhwürth, Stefanie, Krieger, Sigurd, Winter, Katharina, Rosner, Margit, Mikula, Mario, Weichhart, Thomas, Bittman, Robert, Hengstschläger, Markus, Stangl, Herbert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6487575/
https://ncbi.nlm.nih.gov/pubmed/24713582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbalip.2014.03.014
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak